WIXOM, Mich., April 19, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it has hired Raymond Pratt, M.D., as Chief Medical Officer. Dr. Pratt will oversee the clinical development and FDA regulatory process for Rockwell’s Soluble Ferric Pyrophosphate (SFP) and manage all aspects of clinical research and development for SFP and new drug indications.
